Nasdaq

Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing ...
Yahoo Finance

Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis

SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the DARE-BVFREE Phase 3 ...
Nasdaq

Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit (Day 7-14) after a single administration in an investigator-initiated proof of concept study SAN DIEGO, ...
Reuters

Daré Bioscience Announces Initiation Of Pivotal Phase 3 Study Of DARE-BV1

* DARE BIOSCIENCE INC - CONTINUE TO ANTICIPATE REPORTING TOPLINE DATA FROM PHASE 3 STUDY OF DARE-BV1 IN 2020 * DARE BIOSCIENCE INC - IF SINGLE PHASE 3 STUDY IS SUCCESSFUL, INTEND TO FILE A NEW DRUG ...
Yahoo Finance

Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) accepted for ...
CNN

Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit after a single administration in an investigator-initiated proof of concept study, which is higher than ...
The Globe and Mail

Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

NDA supported by positive data from the DARE-BVFREE Phase 3 study, which demonstrated clinical cure rates of 70-81% from a single vaginal dose of DARE-BV1. Ongoing strategic discussions underway to ...
Reuters

Daré Bioscience Receives FDA Fast Track Designation For Dare-Bv1 To Treat Bacterial Vaginosis

* DARE BIOSCIENCE - PLANS TO INITIATE PHASE 3 CLINICAL STUDY OF DARE-BV1 IN ABOUT 220 WOMEN WITH ANTICIPATED TOPLINE DATA READOUT BY END OF 2020 * DARE BIOSCIENCE - INTENDS TO FILE NDA FOLLOWING ...